Tatva Chintan Pharma Chem Share Price
Small Cap | Chemicals | NSE: TATVA | BSE: 543321
₹706.95 
2.45 (0.35 %)
Last Updated: 02 May 2025 02:17 PM
Technicals
BULLISH
BULLISHOverview
Open (₹) 707.90
High (₹) 729.00
Low (₹) 700.05
Prev. Close (₹) 704.50
Volume 12,290
VWAP (₹) 727.86
ROCE (%) 6.77
Industry P/E 59.58
TTM P/E 115.70
P/B Ratio 2.24
Market Cap (₹) Cr.1,653.70
Dividend Yield (%)0.28
EPS (₹) 13.26
ROE4.21%
Sales Growth (%) -7.11
Profit Growth (%)-33.27
Day Range
729.00729.00
52 Week Range
610.001,280.00
Historical Returns
Returns (6M)
-17.45 %
Returns (1Y)
-42.44 %
Returns (3Y)
-69.01 %
Returns (5Y)
-69.43 %
Returns (6M)
-17.45 %
Returns (1Y)
-42.44 %
Returns (3Y)
-69.01 %
Returns (5Y)
-69.43 %
SWOT Analysis
- Company with Low Debt
- Book value per share improving over the last 2 years
- Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
- Strong short-term momentum: Price above short-term moving averages (EMA_10)
- Bullish MACD crossover (12,6,9) indicates potential upward price movement.
- High CCI indicates strong upward momentum.
Technicals
Technical Rating
Trend BULLISH
BULLISHMoving Averages
Technical Indicators
Bullish
Bearish
RSI 48.96
MFI 37.19
ATR 36.90
Commodity Channel Index 100.02
ROC125 -28.52
ROC21 13.34
Williams %R -14.46
Resistance & Support
| Type | Resistance 1 | Resistance 2 | Resistance 3 | PP | Support 1 | Support 2 | Support 3 |
|---|---|---|---|---|---|---|---|
| Current | 732.30 | 742.60 | 750.20 | 724.70 | 714.40 | 706.80 | 696.50 |
| Week Ago | 660.70 | 672.10 | 681.15 | 651.65 | 640.25 | 631.20 | 619.80 |
| Month Ago | 646.80 | 654.30 | 667.20 | 633.90 | 626.40 | 613.50 | 606.00 |
EMA & SMA
706.95
Current Price
Bullish Moving Averages
15
Bearish Moving Averages
5
5 Day 682.91
9 Day 694.28
10 Day 699.67
12 Day 694.32
14 Day 696.56
20 Day 691.67
26 Day 692.09
50 Day 707.74
100 Day 781.03
200 Day 891.23
Deals & Announcements
Bulk and Block Deals
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| VAIBHAV STOCK AND DERIVATIVES BROKING PRIVATE LIMITED | bulk | Sell | 29th Jul, 2021 | ₹2,326.07 | 1,40,469 | NSE |
| NUMIV RESEARCH PRIVATE LIMITED | bulk | Sell | 29th Jul, 2021 | ₹2,319.84 | 2,47,676 | NSE |
| NK SECURITIES RESEARCH PRIVATE LIMITED | bulk | Sell | 29th Jul, 2021 | ₹2,340.16 | 5,81,308 | NSE |
| ALPHAGREP SECURITIES PRIVATE LIMITED | bulk | Sell | 29th Jul, 2021 | ₹2,328.08 | 1,49,145 | NSE |
| VAIBHAV STOCK AND DERIVATIVES BROKING PRIVATE LIMITED | bulk | Buy | 29th Jul, 2021 | ₹2,325.08 | 1,40,469 | NSE |
| PLUTUS WEALTH MANAGEMENT LLP | bulk | Buy | 29th Jul, 2021 | ₹2,171.74 | 6,50,000 | NSE |
| NUMIV RESEARCH PRIVATE LIMITED | bulk | Buy | 29th Jul, 2021 | ₹2,317.81 | 2,47,676 | NSE |
| NK SECURITIES RESEARCH PRIVATE LIMITED | bulk | Buy | 29th Jul, 2021 | ₹2,337.65 | 5,81,308 | NSE |
| ALPHAGREP SECURITIES PRIVATE LIMITED | bulk | Buy | 29th Jul, 2021 | ₹2,329.07 | 1,49,145 | NSE |
Insider Trading
| Date | Name | Action | Avg. Price | Quantity | Deal Value |
|---|---|---|---|---|---|
| 7th Sept, 2023 | Ajay Mansukhlal Patel HUF | Disposal | ₹1,642.12 | 2,06,366 | NSE |
| 7th Sept, 2023 | Priti Ajay Patel | Disposal | ₹1,658.98 | 20,211 | NSE |
| 7th Sept, 2023 | Darshana Nitinkumar Shah | Disposal | ₹1,639.60 | 2,33,766 | NSE |
| 7th Sept, 2023 | Shekhar Rasiklal Somani | Disposal | ₹1,647.83 | 2,33,767 | NSE |
| 7th Sept, 2023 | Ajay Mansukhlal Patel | Disposal | ₹1,641.21 | 7,190 | NSE |
Corporate Actions
| Announcement Date | Subject | Ex - Date | Record Date |
|---|---|---|---|
| 3rd May, 2024 | Rs.2.0000 per share(20%)Final Dividend | 6th Sept, 2024 | 1st Jan, 1970 |
| 5th May, 2023 | Rs.2.0000 per share(20%)Final Dividend | 8th Sept, 2023 | 1st Jan, 1970 |
| 25th Apr, 2022 | Rs.2.0000 per share(20%)Final Dividend | 8th Sept, 2022 | 9th Sept, 2022 |
Announcements
| Date | Source | Detail |
|---|---|---|
| 29th Apr, 2025 | BSE India | <b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Tatva Chintan Pharma Chem Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L24232GJ1996PLC029894</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2024-2025</td> </tr> <tr><td colspan=''3''>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>FY 2024-25 and FY 2025-26</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d), which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)(f) = (b) - (c) - (e) If the calculated value is zero or negative, write 'nil'*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=''2''><b>Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>FY 2023-24 and FY 2024-25</td></tr> <tr><td>Amount of fine to be paid for the block, if applicable Fine = 0.2% of (d) - (e)#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>Ishwar Nayi</td></tr><tr><td>Designation :-</td><td>Company Secretary and Compliance Officer</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>Ashok Bothra</td></tr> <tr><td>Designation : -</td><td>Chief Financial Officer</td></tr></table><div> <br/> Date: 29/04/2025<br/><br/></div> |
| 29th Apr, 2025 | BSE India | <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Tatva Chintan Pharma Chem Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24232GJ1996PLC029894</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr)</td> <td>0.64</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>A-</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>CRISIL LTD.</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=''float:left;''> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No</div> <br/><br/><br/> <div style=''float:left;''> Name of the Company Secretary: Ishwar Nayi <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: cs@tatvachintan.com</div> <div ''style=float:left;margin-left:50px;''> Name of the Chief Financial Officer: Ashok Bothra <br/> Designation: Chief Financial Officer <br/> EmailId: finance@tatvachintan.com</div> </div> <div> <br/> Date: 29/04/2025<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div> |
| 28th Apr, 2025 | BSE India | In continuation of our earlier announcement dated 25 April 2025, we would like to inform that the Earnings Call post announcement of financial results of the Company for the quarter and financial year ended 31 March 2025, which was scheduled to be held on Friday, 02 May 2025 at 05:00 p.m. IST has been rescheduled on Monday, 05 May 2025 at 05:00 p.m. IST.\r\n\r\nThe Call is hosted by ICICI Securities and an invite in this regard is attached for your information and records. |
| 28th Apr, 2025 | NSE India | Tatva Chintan Pharma Chem Limited has informed the Exchange about Schedule of meet |
| 25th Apr, 2025 | BSE India | Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we would like to inform you that the Earnings Call post announcement of financial results of the Company for the quarter and financial year ended 31 March 2025, is scheduled on Friday, 02 May 2025 at 05:00 p.m. IST.\r\n\r\nThe Call is hosted by ICICI Securities and an invite in this regard is attached for your information and records. |
| 25th Apr, 2025 | NSE India | Tatva Chintan Pharma Chem Limited has informed the Exchange about Schedule of meet |
| 25th Apr, 2025 | NSE India | TATVA CHINTAN PHARMA CHEM LIMITED has informed the Exchange about Board Meeting to be held on 02-May-2025 to consider and approve the Yearly Audited Financial results of the Company for the period ended March 2025 and Dividend. |
| 25th Apr, 2025 | BSE India | Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2025 ,inter alia, to consider and approve 1. consider and approve and take on record the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31 March 2025;\r\n\r\n2. consider and recommend a final dividend, if any, on the equity shares of the Company for the financial year ended 31 March 2025, subject to approval of the shareholders at the ensuing Annual General Meeting of the Company.\r\n\r\nFurther, in accordance with the Company''s Code of Conduct for Prohibition of Insider Trading, the Company has intimated its ''''designated persons'''' regarding the closure of the Trading Window for trading in the Company''s equity shares from 01 April 2025 till the expiry of 48 hours from the date the said financial results are made public. |
| 19th Apr, 2025 | NSE India | Tatva Chintan Pharma Chem Limited has informed the Exchange regarding ''Intimation of change in contact details of MUFG Intime India Private Limited, Registrar and Share Transfer Agent (""RTA"") of the Company.''. |
| 19th Apr, 2025 | BSE India | Intimation of change in contact details of MUFG Intime India Private Limited, Registrar and share Transfer Agent (\RTA\) of the Company. |
Board Meetings
| Purpose | Details | Meeting Date | Broadcast Date |
|---|---|---|---|
| Audited Results & Final Dividend | -- | 28th Apr, 2025 | 2nd May, 2025 |
| Quarterly Results | -- | 20th Jan, 2025 | 28th Jan, 2025 |
| Quarterly Results | -- | 17th Oct, 2024 | 25th Oct, 2024 |
| Quarterly Results | -- | 18th Jul, 2024 | 24th Jul, 2024 |
| Audited Results & Final Dividend | -- | 25th Apr, 2024 | 3rd May, 2024 |
| Quarterly Results | -- | 12th Jan, 2024 | 20th Jan, 2024 |
| Quarterly Results | -- | 23rd Oct, 2023 | 2nd Nov, 2023 |
| Quarterly Results | -- | 28th Jul, 2023 | 4th Aug, 2023 |
| Preferential issue of shares | -- | 11th Jul, 2023 | 11th Jul, 2023 |
| Audited Results & Final Dividend | -- | 26th Apr, 2023 | 5th May, 2023 |
Share Holding Pattern
Loading...
Loading...
| Owner Name | Mar, 2025 | Sept, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
|---|---|---|---|---|---|
| Promoter Group | 72.02% | 72.02% | 72.02% | 79.17% | 79.17% |
| Foreign Institutions + | 3.3% | 3.33% | 4.21% | 3.74% | 2.91% |
| Domestic Institutions + | 5.46% | 6.83% | 13.06% | 11.52% | 7.87% |
| Government | 0% | 0% | 0% | 0% | 0% |
| Public | 19.22% | 17.82% | 10.71% | 5.57% | 10.05% |
| Others | 0% | 0% | 0% | 0% | 0% |
About Tatva Chintan Pharma Chem
Tatva Chintan Pharma Chem is a Public Limited Listed company incorporated on 12/06/1996 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24232GJ1996PLC029894 and registration number is 029894. Currently Company is involved in the business activities of Manufacture of organic and inorganic chemical compounds. Company’s Total Operating Revenue is Rs. 378.68 Cr. and Equity Capital is Rs. 23.39 Cr. for the Year ended 31/03/2024.
Parent Organisation
Not Applicable
Founded
1996
Managing Director
Mr. Chintan Nitinkumar Shah
NSE Symbol
TATVA
Tatva Chintan Pharma Chem Management
| Name | Designation |
|---|---|
| Mr. Chintan Nitinkumar Shah | Chairman & Managing Director |
| Mr. Ajaykumar Mansukhlal Patel | Whole Time Director |
| Mr. Shekhar Rasiklal Somani | Whole Time Director |
| Dr. Manher Chimanlal Desai | Independent Director |
| Mr. Subhash Ambubhai Patel | Independent Director |
| Dr. Avani Rajesh Umatt | Independent Director |
Peer Comparison
| Stocks | Market Cap | Market Price | 52 Week Low-High |
|---|---|---|---|
| Pidilite Industries | ₹1,54,318.95 | ₹3,003.50  ₹3,033.90(-1.00%) | ₹2,620.150 - ₹3,414.400 |
| Gujarat Fluorochemicals | ₹42,761.31 | ₹3,862.00 ₹3,892.70(-0.79%) | ₹2,480.000 - ₹4,875.000 |
| Apar Industries | ₹22,506.31 | ₹5,527.00 ₹5,603.00(-1.36%) | ₹4,270.000 - ₹11,797.350 |
| Himadri Speciality Chemical | ₹21,615.79 | ₹434.95 ₹437.70(-0.63%) | ₹307.300 - ₹688.500 |
| Aarti Industries | ₹15,271.16 | ₹427.75  ₹421.25(1.54%) | ₹347.350 - ₹767.100 |
FAQs on Tatva Chintan Pharma Chem
What is the share price of Tatva Chintan Pharma Chem?
The share price of Tatva Chintan Pharma Chem on 2nd May, 2025 is ₹ 706.95.
What is 52W high and 52W low share price of Tatva Chintan Pharma Chem?
The highest and lowest 52W share prices of Tatva Chintan Pharma Chem are ₹ 1280.000 and ₹ 610.000
What is the market cap of Tatva Chintan Pharma Chem?
The market capitalization of Tatva Chintan Pharma Chem as of 2nd May, 2025 is ₹ 1,653.70 Crores
What is the P/E ratio of Tatva Chintan Pharma Chem?
The current P/E ratio of Tatva Chintan Pharma Chem as of 2nd May, 2025 is 59.58
What is the PB ratio of Tatva Chintan Pharma Chem?
The PB ratio of Tatva Chintan Pharma Chem as of 2nd May, 2025 is 2.24
Top Gainers
₹78.00
₹65.00 (0.20%)
₹121.03
₹100.86 (0.20%)
₹13.15
₹11.00 (0.20%)
₹1.88
₹1.57 (0.20%)
Top Losers
₹107.95
₹123.00 (-0.12%)
₹0.50
₹0.56 (-0.11%)
₹24.55
₹28.11 (-0.13%)
₹3.34
₹3.80 (-0.12%)
Market Indices
Sensex
₹80,242.24
₹80,288.38 (0.00%)
Source : Dion Global Solutions Limited